Author Archives: Patricia Silva PhD

IPF Celebrity Supporters: Ray Winstone

Pulmonary fibrosis is a rare but life-threatening disease, for which there is currently no cure. One of the main claims of advocates is that it does not receive the funding or attention needed, unlike other diseases such as lung cancer. Therefore, many people join the work of organizations…

IPF Patients and Doctors on Lookout for New Treatment Approaches

Spherix Global Insights, GmbH, a business intelligence and market research company based on Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled “…

Top 10 Pulmonary Fibrosis Articles of 2015

Throughout 2015, Pulmonary Fibrosis News reported on studies in the field of pulmonary fibrosis care, treatment and disease management, as well as on events related to the condition. As the year comes to an end, here are the 10 articles most widely read by Pulmonary Fibrosis News readers, patients, caregivers and their…

UVA Joins Pulmonary Fibrosis Foundation’s Care Center Network

The University of Virginia Health System (UVA) recently joined the Pulmonary Fibrosis Foundation (PFF)’s Care Center Network, making it one of 19 new facilities chosen after careful peer review for inclusion in this signature PFF program. The PFF Care Center Network now comprises 40 medical centers with expertise in the…

‘Organs on Chips’ May Revolutionize Lung, Other Disease Research

Researchers at the University of Miami (UM), led by Assistant Professor Ashutosh Agarwal, are developing functional organs able to mimic real human organs. These laboratory-developed structures, based on chips, could revolutionize approaches to disease treatment by allowing researchers to peer into organs and their related diseases. The research team used an innovative approach…

IPF Patients with Chronic Cough Sought for Phase 2 Clinical Trial

Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the central nervous…